This article has been updated with information from a company conference call, share price movement, and comments from a Seeking Alpha analyst. Cassava Sciences (NASDAQ:SAVA) said it recorded a $40M ...

Cassava Sciences' stock has declined significantly since its peak, with ongoing skepticism about the efficacy of its Alzheimer's drug, simufilam. Phase 3 trial results for simufilam are anticipated by ...

AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational ...

When I first encountered a cassava plant, it was love at first sight, and over the years, my affection for this graceful and highly useful perennial has only increased. Inside the US, cassava is ...

International teams are working to bring the starchy root’s genetics into the 21st century and help food-insecure countries Cassava is a starchy, tuberous root first domesticated about 10,000 years ...